Lecture delivered at forum showcasing regenerative medicine talent policies and latest technology trends
[by Ji, Yong Jun] ENCell, a contract development and manufacturing organization (CDMO) specializing in advanced biopharmaceuticals and novel drug development, announced on July 18 that its CEO, Chang Jong-wook, delivered an oral presentation titled ‘From preclinical to commercialization of cell and gene therapy: The key role of CDMO’ at the 2025 Advanced Regenerative Medicine Human Resources Development Forum. The event was co-hosted by the Regenerative Medicine Acceleration Foundation, the Korean Tissue Engineering and Regenerative Medicine Society, the Korean Society for Stem Cell Research, and the Korean Society of Gene and Cell Therapy.
In his presentation, Chang provided an overview of global trends and industry analyses in the field of cell and gene therapy (CGT), shared insights and case studies drawn from his experiences since founding 카지노 바카라, and offered recommendations for the development of the CGT industry.
카지노 바카라 has established the foundation for 100% domestic production by adopting Korea’s proprietary CGT source technology. Highlighting the challenges faced in the past, when gene therapies had to be entirely imported from overseas, the company also discussed its recent collaboration with the Korea Research Institute of Bioscience & Biotechnology (KRIBB) to develop and manufacture a customized adeno-associated virus (AAV) gene therapy platform valued at KRW 5.7 billion (approximately USD 4 million).
The KRIBB, in collaboration with 카지노 바카라, aims to establish a clinical production platform for the development of customized AAV gene therapies, envisioned as a potential next-generation growth engine for the country. The initiative seeks to lay the groundwork for the domestic introduction and commercialization of AAV gene therapies developed using Korea’s proprietary technologies.
Chang emphasized that the Korean CGT market is serving as a catalyst in shaping a new trend in the biotechnology industry, transitioning from its early development phase into a growth stage. 카지노 바카라 delivers tailored CDMO solutions through a differentiated production and quality management system, offering integrated one-stop services. These are supported by Korea’s only globally compliant pharmaceutical manufacturing and quality control standard (GMP) facility capable of simultaneous cell and viral vector production. To date, the company has secured 34 projects from 18 clients, with cumulative sales in the CDMO sector reaching KRW 31.4 billion.
카지노 바카라’s investigational new drug candidate, ‘EN001 (development code),’ was designated as an ‘orphan drug’ by the U.S. Food and Drug Administration (FDA) in February for the treatment of patients with Charcot-Marie-Tooth disease. The company is currently preparing an advanced regenerative medicine treatment specifically targeting Charcot-Marie-Tooth disease type 1E, in accordance with a recent amendment to the Advanced Biopharmaceuticals Act.
“This forum provided a valuable opportunity to discuss emerging trends and future directions in the fields of advanced regenerative medicine and CGT,” Chang said. “Building on 카지노 바카라’s continued efforts to contribute to the growth of the overall CGT market since its founding, we will remain committed to ensuring that these trends of the biotechnology industry extend to various sectors,” he added.